References
- 1. Adeleye JO, Emuze ME, Azeez TA, Esan A, Akande TO, Balogun WO. Clinical profiles of males with Graves’ disease: a two year review in a tertiary hospital in Nigeria. J Clin Biomed Res. 2020;2:1-2.
- 2. Samuels MH. Most patients with Graves’ disease treated with additional anti-thyroid drugs eventually require additional therapies. Clin Thyroidol. 2020;32:9-11.10.1089/ct.2020;32.9-11
- 3. Dhali TK, Chahar M. Thyroid dermopathy – a diagnostic clue of hidden hyperthyroidism. Dermatoendocrinol. 2014;6:e981078.10.4161/19381980.2014.981078
- 4. Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab. 2002;87:438-446.10.1210/jcem.87.2.8220
- 5. Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest. 2002;110:161-164.10.1172/JCI0216234
- 6. Nair PA, Mishra A, Chaudhary A. A pretibial myxedema associated with euthyroid Hashimoto thyroiditis: a case report. J Clin Diagn Res. 2014;8:1-2.10.7860/JCDR/2014/6581.4415
- 7. Peacey SR, Flemming L, Messenger A, Weetman AP. Is Graves’ dermopathy a generalized disorder? Thyroid. 1996;6:41-45.10.1089/thy.1996.6.41
- 8. Sabanova E, Fadeyev V, Lvov A. Thyroid dermopathy: clinical features in Graves’ disease. Endocrine Abstracts. 2019;63:1217.10.1530/endoabs.63.P1217